BioCardia is focusing on submitting CardiAMP Cell Therapy for ischemic heart failure approval to Japan's PMDA by the end of 2026, targeting an initial patient subgroup of 20,000 with a potential reimbursement of $124,000 per procedure. The company is also enrolling patients in the CardiAMP HF II trial in the U.S., which may support FDA premarket approval. BioCardia's Helix delivery system and Heart3D imaging platform support multiple biotherapeutic programs, with ongoing discussions for partnerships in gene, cell, and protein therapies. The recent financing will fund these efforts, with key milestones including regulatory submissions and strategic partnerships expected to drive value creation.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
